Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Benzinga · 3d ago
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.